21 May 2009
Liver transplantation as a treatment of hepatoblastoma – single center experience
H Ismail, D Broniszczak, P Kaliciński, B Bagińska-Dembowska, D Perek, P Kluge, A Kościesza, A LembasAnn Transplant 2009; 14(1): 27-27 :: ID: 880297
Abstract
Background: Hepatoblastoma (HBL) is the most common primary hepatic tumour in children. The aim of the study was retrospective analysis of the type of management and its results in children with HBL in our centre for over the last 19 years.
Material/Methods: Between 1990 and 2008 there were 44 children with hepatoblastoma treated in our centre. All patients were treated with various protocols of chemotherapy. In 32 children partial resection of liver was performed, in 9 with unresectable tumour liver - transplantation. Among them there were 2 pts with pulmonary metastases cleared by chemotherapy, and 2 with local tumour recurrence after resection done elsewhere. In three children with inoperable disease (unresectable tumour and pulmonary and bone metastases) only palliative chemotherapy was administered.
Results: There were 9 deaths among children treated with liver resection (28.1%), and 4 deaths in the group treated with liver transplantation (44.4%), but only 1 in 7 patients with local recurrence would was excluded (14.3%). Overall survival rate among all 44 children with HBL was 64%. Follow-up of living patients who underwent resection ranges from 1 to 190 months (mean 80
months). All deaths were due to recurrence of the disease. Follow-up of living patients who were transplanted ranges from 22 to 78 months (mean 42 months). The cause of death in OLTx group was recurrence of the disease (in metastatic form) in 3 patients and PTLD in 1 patient. All 3 children who were not qualified for surgical treatment died of hepatoblastoma.
Conclusions: With the improved selection for the two types of surgical treatment: partial liver resection or total hepatectomy and liver transplantation excellent results can be obtained in children with hepatoblastoma limited to the liver (including pts with cleared pulmonary metastases). Prognosis for the patients with recurrent disease or with inoperable tumour remains poor despite improved chemotherapy.
Keywords: Liver Transplantation
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






